[go: up one dir, main page]

CL2013001472A1 - Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos. - Google Patents

Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos.

Info

Publication number
CL2013001472A1
CL2013001472A1 CL2013001472A CL2013001472A CL2013001472A1 CL 2013001472 A1 CL2013001472 A1 CL 2013001472A1 CL 2013001472 A CL2013001472 A CL 2013001472A CL 2013001472 A CL2013001472 A CL 2013001472A CL 2013001472 A1 CL2013001472 A1 CL 2013001472A1
Authority
CL
Chile
Prior art keywords
weight
oligosaccharide
reduction
oligosarides
galacto
Prior art date
Application number
CL2013001472A
Other languages
English (en)
Inventor
Norbert Sprenger
Jean-Richard Neeser
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of CL2013001472A1 publication Critical patent/CL2013001472A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/04—Disaccharides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Pediatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Polyurethanes Or Polyureas (AREA)
CL2013001472A 2010-11-23 2013-05-23 Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos. CL2013001472A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10192232A EP2455387A1 (en) 2010-11-23 2010-11-23 Oligosaccharide mixture and food product comprising this mixture, especially infant formula

Publications (1)

Publication Number Publication Date
CL2013001472A1 true CL2013001472A1 (es) 2014-05-09

Family

ID=44168484

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013001472A CL2013001472A1 (es) 2010-11-23 2013-05-23 Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos.

Country Status (19)

Country Link
US (2) US9161563B2 (es)
EP (2) EP2455387A1 (es)
CN (1) CN103797021B (es)
AU (1) AU2011333860C1 (es)
BR (1) BR112013012546A2 (es)
CA (1) CA2818505A1 (es)
CL (1) CL2013001472A1 (es)
ES (1) ES2534882T3 (es)
IL (1) IL226277A0 (es)
MX (1) MX338383B (es)
MY (1) MY184985A (es)
PH (1) PH12013500951B1 (es)
PL (1) PL2643336T3 (es)
PT (1) PT2643336E (es)
RU (1) RU2560190C2 (es)
SG (1) SG190262A1 (es)
TW (1) TW201225852A (es)
WO (1) WO2012069415A1 (es)
ZA (1) ZA201304643B (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2658549B1 (en) 2010-12-31 2020-06-03 Abbott Laboratories Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents
MY171620A (en) 2010-12-31 2019-10-21 Abbott Lab Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers or children using human milk oligosaccharides
MY171851A (en) 2011-06-20 2019-11-04 Heinz Co Brands H J Llc Probiotic compositions and methods
BR112014001472A2 (pt) 2011-07-22 2017-02-21 Abbott Lab galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
HK1199607A1 (en) 2011-08-29 2015-07-10 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
AU2012324985B2 (en) 2011-10-18 2016-01-07 Société des Produits Nestlé S.A. Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery
AU2012324993B2 (en) 2011-10-18 2015-11-26 Société des Produits Nestlé S.A. Composition for use in the promotion of magnesium absorption and/or magnesium retention
DE202013012829U1 (de) 2012-06-14 2020-03-04 Glycom A/S Verbesserung der Stabilität und Reinheit sowie Erhöhung der Bioverfügbarkeit von menschlichen Milch-Oligosacchariden oder Vorläufern oder Mischungen davon
US20150182549A1 (en) * 2012-06-22 2015-07-02 Glycom A/S Method for enzymatic glycosylation of oligosaccharides from mammalian animal milk
WO2013190529A1 (en) * 2012-06-22 2013-12-27 Glycom A/S Glycosylated galactosyl disaccharddes, methods for their production and their use in consumable products
EP2943500B1 (en) * 2012-11-13 2017-11-08 Glycom A/S Crystalline 3-o-fucosyllactose
WO2014100696A1 (en) * 2012-12-20 2014-06-26 Abbott Laboratories Nutritional formulations using human milk oligosaccharides for modulating inflammation
US10940158B2 (en) 2013-11-15 2021-03-09 Societe Des Produits Nestle S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants or young children born by C-section
CN105682664A (zh) * 2013-11-15 2016-06-15 雀巢产品技术援助有限公司 利用岩藻糖基化低聚糖预防或治疗非分泌型母亲诞下或喂养的婴儿的变态反应的组合物，尤其适用于有风险的婴儿或剖腹产婴儿
ES2895380T3 (es) 2013-11-15 2022-02-21 Nestle Sa Composiciones para su uso en la prevención o tratamiento de la enterocolitis necrotizante en bebés y niños pequeños
WO2015077233A1 (en) 2013-11-19 2015-05-28 Abbott Laboratories Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides
EP2885977A1 (en) * 2013-12-19 2015-06-24 Agriculture and Food Development Authority (TEAGASC) An oligosaccharide-enriched composition having immune-modulatory and anti-adhesion properties
ES2701163T3 (es) 2014-01-20 2019-02-21 Jennewein Biotechnologie Gmbh Procedimiento para la purificación eficiente de oligosacáridos de la leche humana (HMO) neutros a partir de la fermentación microbiana
EP3673909A1 (en) 2014-04-08 2020-07-01 Abbott Laboratories Nutritional compositions for use in treating enteric infection comprising human milk oligosaccharides
CA2954662C (en) 2014-07-09 2024-03-19 Midori Usa, Inc. Oligosaccharide compositions and methods for producing thereof
WO2016122887A1 (en) 2015-01-26 2016-08-04 Midori Usa, Inc. Oligosaccharide compositions for use animal feed and methods of producing thereof
PH12017550041B1 (en) 2015-03-05 2022-08-05 Socia‰Ta‰ Des Produits Nestla‰ S A Compositions for use in improving stool consistency or frequency in infants or young children
ES2772685T3 (es) * 2015-08-04 2020-07-08 Nestle Sa Composiciones nutricionales con 2FL y LNNT para inducir una microbiota intestinal similar a la de los bebés lactantes
CN108366581B (zh) 2015-12-18 2022-04-19 雀巢产品有限公司 含来自采用至少一种内肽酶的连续方法的水解蛋白的热灭菌高蛋白质组合物
WO2017129642A1 (en) * 2016-01-26 2017-08-03 Nestec S.A. Composition for use in the prevention and/or treatment of skin conditions and skin diseases
US11224651B2 (en) 2016-01-26 2022-01-18 Societe Des Produits Nestle S.A. Compositions comprising human milk oligosaccharides for use in infants or young children to prevent or treat allergies
WO2017129644A1 (en) * 2016-01-26 2017-08-03 Nestec S.A. Compositions with specific oligosaccharides to prevent or treat allergies
CN108472274B (zh) * 2016-01-26 2025-08-19 雀巢产品有限公司 用于预防或减少经皮水分流失的组合物
US10039765B1 (en) * 2016-02-26 2018-08-07 Michelle Ann Toothman Vitamin supplement compositions with enhanced bioavailability
US10039805B1 (en) * 2016-02-26 2018-08-07 Michelle Ann Toothman Infant formulas having vitamin complexes with enhanced bioavailability
US11122833B1 (en) * 2016-02-26 2021-09-21 Michelle Ann Toothman Infant formulas having vitamin complexes with enhanced bioavailability
US10617700B1 (en) * 2016-02-26 2020-04-14 Michelle Ann Toothman Vitamin supplement compositions with enhanced bioavailability
WO2017190755A1 (en) * 2016-05-05 2017-11-09 Glycom A/S Composition comprising hmos for use in the treatment of mast cell mediated visceral hypersensitivity and/or pain
US20180103675A1 (en) * 2016-10-14 2018-04-19 Mead Johnson Nutrition Company Personalized pediatric nutrition products comprising human milk oligosaccharides
WO2019038668A1 (en) * 2017-08-21 2019-02-28 Glycom A/S SYNTHETIC COMPOSITION TO REDUCE ALLERGY SYMPTOMS
JP7291702B2 (ja) * 2017-12-08 2023-06-15 クリスチャン・ハンセン・ハーエムオー・ゲーエムベーハー ヒトミルクオリゴ糖の噴霧乾燥混合物
CN109731000B (zh) * 2018-12-25 2021-02-19 东北农业大学 2’-岩藻糖基乳糖的应用
EP3981256A4 (en) * 2019-06-05 2023-01-25 Morinaga Milk Industry Co., Ltd. COMPOSITION
CA3163781A1 (en) * 2019-12-30 2021-07-08 Societe Des Produits Nestle S.A. Infant formula
US11285105B2 (en) * 2020-07-28 2022-03-29 Igh Naturals, Inc. Compositions and methods for improving gastrointestinal absorption of electrolytes
US20240138457A1 (en) * 2021-03-09 2024-05-02 Frieslandcampina Nederland B.V. Aqueous composition comprising gos and hmo
CN114145356B (zh) * 2021-11-30 2023-11-10 内蒙古伊利实业集团股份有限公司 一种可改善免疫应答的配方奶粉及其制备方法与应用
US12527342B2 (en) * 2024-01-12 2026-01-20 Nutifood Nutrition Food Joint Stock Company Supplementary composition containing 2′-fucosyllactose (2′-fl) and fructo-oligosaccharide (FOS) with synergistic effects on the digestive and immune systems for children, and process of manufacturing a children formula containing said supplementary composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19958985A1 (de) * 1999-12-07 2001-06-13 Nutricia Nv Oligosaccharidmischung
DE60301677T2 (de) * 2002-02-04 2006-07-06 Kyowa Hakko Kogyo Co., Ltd. Pharmazeutische und Lebenmittelzusammensetzungen mit einem Di- oder Oligosaccharid, das die Insulinfreisetzung steigert
ATE414428T1 (de) * 2003-10-24 2008-12-15 Nutricia Nv Symbiotische zusammensetzung für kleinkinder
JP5236189B2 (ja) * 2003-12-05 2013-07-17 チルドレンズ ホスピタル メディカル センター オリゴ糖組成物および感染症の治療における該組成物の使用
ES1056525Y (es) * 2004-01-13 2004-07-16 Perez Alfredo Pineiro Halador de tres rodillos para redes y aparejos de pesca.
MX2007010094A (es) * 2005-02-21 2007-09-25 Nestec Sa Mezcla de oligosacarido.
RU2430631C2 (ru) * 2006-02-10 2011-10-10 Нестек С.А. Пребиотическая смесь олигосахаридов и пищевой продукт, ее содержащий
AU2007222598B2 (en) * 2006-03-07 2013-01-10 Société des Produits Nestlé S.A. Synbiotic mixture
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
EP1974743A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CA2705145A1 (en) 2007-11-07 2009-05-14 Mead Johnson Nutrition Company Method for decreasing bitterness and improving taste of protein-free and hydrolyzed infant formulas
EP2072052A1 (en) * 2007-12-17 2009-06-24 Nestec S.A. Prevention of opportunistic infections in immune-compromised subjects
EP2143341A1 (en) * 2008-07-08 2010-01-13 Nestec S.A. Nutritional Composition Containing Oligosaccharide Mixture
MY182355A (en) * 2009-06-08 2021-01-20 Chr Hansen Hmo Gmbh Hmo synthesis

Also Published As

Publication number Publication date
CA2818505A1 (en) 2012-05-31
MY184985A (en) 2021-04-30
AU2011333860B2 (en) 2016-05-19
EP2643336A1 (en) 2013-10-02
CN103797021B (zh) 2016-08-10
US9161563B2 (en) 2015-10-20
IL226277A0 (en) 2013-07-31
CN103797021A (zh) 2014-05-14
PH12013500951B1 (en) 2017-12-13
EP2455387A1 (en) 2012-05-23
WO2012069415A1 (en) 2012-05-31
PT2643336E (pt) 2015-04-29
US20150335052A1 (en) 2015-11-26
PL2643336T3 (pl) 2015-08-31
SG190262A1 (en) 2013-06-28
RU2013128575A (ru) 2015-01-10
ES2534882T3 (es) 2015-04-29
US20130236423A1 (en) 2013-09-12
ZA201304643B (en) 2016-01-27
MX2013005863A (es) 2013-07-05
TW201225852A (en) 2012-07-01
BR112013012546A2 (pt) 2016-08-09
RU2560190C2 (ru) 2015-08-20
AU2011333860C1 (en) 2017-10-05
MX338383B (es) 2016-04-14
AU2011333860A1 (en) 2013-05-30
PH12013500951A1 (en) 2013-07-08
EP2643336B1 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
CL2013001472A1 (es) Mezcla de oligosaridos que comprende 5-70% en peso de al menos un oligosacarido n-acetilado, 5-90% en peso de al menos un galacto-oligosacarido, 2-50% en peso de al menos un oligosacarido sialilado y 5-70% en peso de al menos un oligosacarido fucosilado; producto alimenticio que la comprende; y su uso para la prevencion y reduccion del riesgo y/o reduccion de la severidad y/o reduccion de la ocurrencia de alergias en alimentos.
CL2013001470A1 (es) Mezcla de oligosacaridos que comprende al menos una acetil-n-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; producto alimenticio que comprende esta mezcla; y su uso para prevenir y reducir el riesgo y/o reducir la severidad y/o reducir la aparicion de alergias a alimentos y los efectos relacionados con la alergia a alimentos sobre la salud.
CL2013001436A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
CL2013001433A1 (es) Composicion que comprende al menos una n-acetil lactosamina, al menos un oligosacarido sialilado al menos un oligosacarido fucosilado; y su uso en la prevencion de infecciones respiratorias agudas y/o para aliviar los sintomas de dichas infecciones.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0816133A2 (pt) Composição que emite flavorizante, dispositivo que emite flavorizante, tablete comprimido ou moldado, produto alimentício acondicionado, e, métodos para fabricar um dispositivo que emite flavorizante e uma composição que emite flavorizante.
WO2010023422A8 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
WO2012156296A8 (en) Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients
IL236123A0 (en) Preparations containing n-[4,2-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-4,1-dihydro-4-oxoquinoline-3-carboxamide for use in the treatment of cftr-mediated disorders
CL2013001471A1 (es) Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel.
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
PH12014501061B1 (en) Tricyclic compounds, compositions comprising them and uses thereof
CL2014000490A1 (es) Compuestos derivados de pirazol y sus sales, con actividad inhibidora de sglt1; composicion farmaceutica que los comprende; y su uso para tratar o prevenir diabetes.
MX391963B (es) Beta-caseina a2 y prevencion de la inflamacion del intestino.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
BR112013019522A2 (pt) dissialil lacto-n-tetraose (dslnt) ou as variantes, os isômeros, os análogos e os derivados da mesma para prevenir ou inibir doença do intestino
WO2011076367A3 (en) Synergistic antiviral composition and use thereof
MY172040A (en) Synergistic dietary supplement for enhancing physical performance
CL2015000434A1 (es) Metodo para el tratamiento, prevencion o disminucion de la severidad de una condicion o trastorno no neoplasico de la piel que comprende administrar un compuesto derivado de retinoides; composicion dermica que comprende los derivados de retinoide.
AR083093A1 (es) Combinacion para reemplazo de grasas para la sustitucion parcial o total de la grasa en productos alimenticios y un producto alimenticio que la contiene
BR112012033739A8 (pt) Isomaltulose para uso no aumento do desempenho mental
BR112014003118A2 (pt) composto que induz atividade de cardiotrofina-1 (ct-1) para uso na prevenção e/ou tratamento de lesão renal aguda, composição e uso de uma composição
CL2013001731A1 (es) Una combinacion farmaceutica sinergica que comprende orlistat o sus sales y resveratrol o sus sales; composicion farmaceutica que comprende a dicha combinacion sinergica; su proceso de preparacion; y su uso para el tratamiento de padecimientos de sobrepeso, obesidad y problemas de salud relacionados.